FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/2/99/014/001 (3 pipettes) EU/2/99/014/012 (15 pipettes)
Estonian: EU/2/99/014/001 (3 pipetti) EU/2/99/014/012 (15 pipetti)
English: Stronghold 15 mg for cats and dogs
Estonian: Stronghold 15 mg kassidele ja koertele
English: For complete elimination of the mites, a single dose of the veterinary medicinal product should be administered for two consecutive months.
Estonian: Lestade täielikuks hävitamiseks manustatakse veterinaarravimit ühekordne annus kahel järjestikusel kuul.
English: For the full list of excipients, see section 6.1.
Estonian: Butüülhüdroksütolueen 0,08% Abiainete täielik loetelu on esitatud lõigus 6.1.
English: The veterinary medicinal product was administered at 3 times the recommended dose to cats and dogs infected with adult heartworms and no undesirable effects were observed.
Estonian: Veterinaarravimi manustamisel täiskasvanud südameussidega nakatunud kassidele ja koertele 3-kordses soovitatavas annuses manustatuna kõrvatoimeid ei esinenud.
English: EU/2/99/014/002 (3 pipettes) EU/2/99/014/008 (6 pipettes) EU/2/99/014/013 (3 pipettes) EU/2/99/014/014 (6 pipettes)
Estonian: EU/2/99/014/002 (3 pipetti) EU/2/99/014/008 (6 pipetti) EU/2/99/014/013 (3 pipetti) EU/2/99/014/014 (6 pipetti)
English: Each single-dose (pipette) delivers: Stronghold 15 mg for cats and dogs
Estonian: Iga üksik Strongholdi annus (pipett) annab: Stronghold 15 mg kassidele ja koertele 6% lahus selamektiin
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON LABEL, 30 mg, 60 mg, 120 mg, 240 mg, 360 mg (3 and 6 pipettes)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PAKENDI KLEEBIS, 30 mg, 60 mg, 120 mg, 240 mg, 360 mg (3 ja 6 pipetti)
English: Stronghold 45 mg for cats
Estonian: Stronghold 45 mg kassidele
English: It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when Stronghold has been administered monthly.
Estonian: Südameusside profülaktika osana on soovitatav, et koeri testitaks perioodiliselt selle infektsiooni suhtes kas siis, kui Strongholdi on manustatud iga kuu.
English: Stronghold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg selamectin
Estonian: Stronghold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg selamektiin
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON LABEL, 45 mg, 60 mg (3 and 6 pipettes)
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PAKENDI KLEEBIS, 45 mg, 60 mg (3 ja 6 pipetti)
English: selamectin 30 mg selamectin 60 mg selamectin 120 mg selamectin 240 mg selamectin 360 mg
Estonian: selamektiin 30 mg selamektiin 60 mg selamektiin 120 mg selamektiin 240 mg selamektiin 360 mg
English: 2.6-7.5 Blue 7.6-10.0 Taupe
Estonian: ≤ 2,5 Roosa 2,6-7,5 Sinine 7,6-10,0 Tumehall
English: Stronghold 120 mg for dogs
Estonian: Stronghold 120 mg koertele
English: The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.
Estonian: Veterinaarravimit võib kasutada ühe komponendina kirbuallergiast tingitud dermatiidi ravis ning kirbumune ja -vastseid tapvate omaduste tõttu võib see aidata kontrollida kirpude esinemist loomaga kokkupuutuvas keskkonnas.
English: Stronghold 240 mg for dogs
Estonian: Stronghold 240 mg koertele
English: PACKAGE LEAFLET: Stronghold spot-on solution
Estonian: PAKENDI INFOLEHT Stronghold täpilahus
English: 12% w/v solution selamectin 120 mg
Estonian: 12% lahus selamektiin 120 mg
English: Butylated hydroxytoluene Dipropylene glycol methyl ether Isopropyl alcohol
Estonian: Butüülhüdroksütolueen, dipropüleenglükoolmetüüleeter, isopropüülakohol.
English: Stronghold 45 mg spot-on solution for cats 2.6-7.5 kg Stronghold 60 mg spot-on solution for cats 7.6-10.0 kg selamectin
Estonian: Stronghold 45 mg täpilahus kassidele kehamassiga 2,6-7,5 kg Stronghold 60 mg täpilahus kassidele kehamassiga 7,6-10,0 kg selamektiin
English: Stronghold 60 mg for cats
Estonian: Stronghold 60 mg kassidele
English: A single dose of the veterinary medicinal product should be administered.
Estonian: Manustatakse toote ühekordne annus veterinaarravimit.
English: Stronghold 360 mg for dogs
Estonian: Stronghold 360 mg koertele
English: 12% w/v solution selamectin 240 mg
Estonian: 12% lahus selamektiin 240 mg
English: Spot-on use
Estonian: Kuidas manustada
English: Stronghold 30 mg for dogs
Estonian: Stronghold 30 mg koertele
English: 12% w/v solution selamectin 360 mg
Estonian: 12% lahus selamektiin 360 mg
English: 6% w/v solution selamectin 45 mg
Estonian: 6% lahus selamektiin 45 mg
English: 6% w/v solution selamectin 15 mg
Estonian: 6% lahus selamektiin 15 mg
English: Prevention of heartworm disease (cats and dogs)
Estonian: Südameusstõve profülaktika (kassid ja koerad)
English: Stronghold 60 mg for dogs
Estonian: Stronghold 60 mg koertele
English: 6% w/v solution selamectin 60 mg
Estonian: 6% lahus selamektiin 60 mg
English: Remove the Stronghold pipette from its protective package.
Estonian: Hoides pipetti püstises asendis, suruge korki allapoole aplikaatori kaitse purunemiseni.
English: 12% w/v solution selamectin 30 mg
Estonian: 12% lahus selamektiin 30 mg
English: Marketing authorisation holder and manufacturer responsible for batch release: Zoetis Belgium SA
Estonian: Müügiloa hoidja ja partii vabastamise eest vastutav tootja:
English: 12% w/v solution selamectin 60 mg
Estonian: 12% lahus selamektiin 60 mg
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS FOIL LABEL, 15 mg, 30 mg, 45 mg, 60 mg, 120 mg, 240 mg, 360 mg
Estonian: PIPETI KLEEBIS, 15 mg, 30 mg, 45 mg, 60 mg, 120 mg, 240 mg, 360 mg (KÕIK PAKENDI SUURUSED)
English: Cats and dogs weighing 2.5 kg or less (Stronghold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg) Dogs weighing 2.6 kg-5.0 kg (Stronghold 30 mg spot-on solution for dogs 2.6-5.0 kg) Cats weighing 2.6 kg-7.5 kg (Stronghold 45 mg spot-on solution for cats 2.6-7.5 kg) Cats weighing 7.6 kg-10.0 kg (Stronghold 60 mg spot-on solution for cats 7.6-10.0 kg) Dogs weighing 5.1 kg-10.0 kg (Stronghold 60 mg spot-on solution for dogs 5.1-10.0 kg) Dogs weighing 10.1 kg-20.0 kg (Stronghold 120 mg spot-on solution for dogs 10.1-20.0 kg) Dogs weighing 20.1 kg-40.0kg (Stronghold 240 mg spot-on solution for dogs 20.1-40.0 kg) Dogs weighing 40.1 kg-60.0 kg (Stronghold 360 mg spot-on solution for dogs 40.1-60.0 kg)
Estonian: Kassid ja koerad kehamassiga kuni 2,5 kg (Stronghold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg) Koerad kehamassiga 2,5-5,0 kg (Stronghold 30 mg täpilahus koertele 2,5-5,0 kg) Kassid kehamassiga 2,6-7,5 kg (Stronghold 45 mg täpilahus kassidele 2,6-7,5 kg) Kassid kehamassiga 7,6-10,0 kg (Stronghold 60 mg täpilahus kassidele 7,6-10,0 kg) Koerad kehamassiga 5,1-10,0 kg (Stronghold 60 mg täpilahus koertele 5,1-10,0 kg) Koerad kehamassiga 10,1-20,0 kg (Stronghold 120 mg täpilahus koertele 10,1-20,0 kg) Koerad kehamassiga 20,1-40,0 kg (Stronghold 240 mg täpilahus koertele 20,1-40,0 kg) Koerad kehamassiga 40,1-60,0 kg (Stronghold 360 mg täpilahus koertele 40,1-60,0 kg)
English: Treatment of hookworm infections (cats)
Estonian: Soolte nugiusside põhjustatud parasitooside ravi (kassid)
English: Apply the tip of the Stronghold pipette directly to the skin without massaging.
Estonian: Asetage Strongholdi pipeti tipp otse vastu looma nahka ja pigistage tuubi, nii et ravim väljuks ühe tilgana.
English: Part the hair at the base of your animal's neck in front of the shoulder blades to expose a small area of skin.
Estonian: Suruge karv looma kaelal lahku ja paljastage nahk.
English: Stronghold 30 mg spot-on solution for dogs 2.6-5.0 kg Stronghold 60 mg spot-on solution for dogs 5.1-10.0 kg Stronghold 120 mg spot-on solution for dogs 10.1-20.0 kg Stronghold 240 mg spot-on solution for dogs 20.1-40.0 kg Stronghold 360 mg spot-on solution for dogs 40.1-60.0 kg selamectin
Estonian: Stronghold 30 mg täpilahus koertele 2,6-5,0 kg Stronghold 60 mg täpilahus koertele 5,1-10,0 kg Stronghold 120 mg täpilahus koertele 10,1-20,0 kg Stronghold 240 mg täpilahus koertele 20,1-40,0 kg Stronghold 360 mg täpilahus koertele 40,1-60,0 kg selamektiin
English: Stronghold 15 mg spot-on for cats and dogs ≤ 2.5 kg Stronghold 30 mg spot-on for dogs 2.6-5.0 kg Stronghold 45 mg spot-on for cats 2.6-7.5 kg Stronghold 60 mg spot-on for cats 7.6-10.0 kg Stronghold 60 mg spot-on for dogs 5.1-10.0 kg Stronghold 120 mg spot-on for dogs 10.1-20.0 kg Stronghold 240 mg spot-on for dogs 20.1-40.0 kg Stronghold 360 mg spot-on for dogs 40.1-60.0 kg selamectin
Estonian: Stronghold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg Stronghold 30 mg täpilahus koertele 2,6-5,0 kg Stronghold 45 mg täpilahus kassidele 2,6-7,5 kg Stronghold 60 mg täpilahus kassidele 7,6-10,0 kg Stronghold 60 mg täpilahus koertele 7,6-10,0 kg Stronghold 120 mg täpilahus koertele 10,1-20,0 kg Stronghold 240 mg täpilahus koertele 20,0-40,0 kg Stronghold 360 mg täpilahus koertele 40,1-60,0 kg selamektiin
English: Stronghold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg Stronghold 30 mg spot-on solution for dogs 2.6-5.0 kg Stronghold 45 mg spot-on solution for cats 2.6-7.5 kg Stronghold 60 mg spot-on solution for cats 7.6-10.0 kg Stronghold 60 mg spot-on solution for dogs 5.1-10.0 kg Stronghold 120 mg spot-on solution for dogs 10.1-20.0 kg Stronghold 240 mg spot-on solution for dogs 20.1-40.0 kg Stronghold 360 mg spot-on solution for dogs 40.1-60.0 kg
Estonian: Stronghold 15 mg täpilahus kassidele ja koertele ≤ 2,5 kg Stronghold 30 mg täpilahus koertele 2,6-5,0 kg Stronghold 45 mg täpilahus kassidele 2,6-7,5 kg Stronghold 60 mg täpilahus kassidele 7,6-10,0 kg Stronghold 60 mg täpilahus koertele 7,6-10,0 kg Stronghold 120 mg täpilahus koertele 10,1-20,0 kg Stronghold 240 mg täpilahus koertele 20,0-40,0 kg Stronghold 360 mg täpilahus koertele 40,1-60,0 kg
English: Veterinary medicinal product subject to prescription.
Estonian: Manustatakse üks annus veterinaarravimit.
English: BELGIUM
Estonian: LISAINFO
English: This is as a result of the adulticidal, larvicidal and ovicidal properties of the veterinary medicinal product.
Estonian: Selle veterinaarravimiomaduste tõttu hukkuvad kirpude täiskasvanud vormid, munad ja larvid.
English: Treatment of biting lice infestations (Felicola subrostratus) Treatment of adult roundworms (Toxocara cati) Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Estonian: • Ümarusside (Toxocara cati) täiskasvanud vormide põhjustatud parasitooside ravi.
English: Rose
Estonian: A.
English: Most of these side effects were mild.
Estonian: Enamik neist kõrvalnähte olid kerged.
English: What measures are being taken to ensure the safe and effective use of Zostavax?
Estonian: Mis meetmed võetakse, et tagada Zostavaxi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zostavax on 19 May 2006.
Estonian: Euroopa Komisjon andis Zostavaxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. mail
English: It must also not be used in patients with active untreated tuberculosis or in pregnant women.
Estonian: Samuti ei tohi seda kasutada aktiivse ravimata tuberkuloosiga patsientidel ega rasedatel naistel.
English: A risk management plan has been developed to ensure that Zostavax is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Zostavaxi võimalikult ohutu kasutamine.
English: The full EPAR for Zostavax is available on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zostavaxi kohta on ameti veebilehel:ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: In patients who have bleeding problems, the vaccine should be given under the skin.
Estonian: Verejooksuprobleemidega patsientidele tuleb vaktsiini süstida naha alla.
English: The patients were followed for 2 to 4.5 years after vaccination.
Estonian: Patsiente kontrolliti pärast vaktsineerimist 2-4,5 aasta vältel.
English: The study was a double-blind trial, which means that neither the doctor nor the patient knew what treatment the patient was receiving.
Estonian: Uuring oli topeltpime, mis tähendab, et ei arst ega patsient ei teadnud, kas patsient sai vaktsiini või platseebot.
English: What is Zostavax?
Estonian: Mis on Zostavax?
English: Zostavax was more effective than placebo in preventing shingles.
Estonian: Zostavax oli efektiivsem kui platseebo vöötohatise ennetamisel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zostavax, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Zostavaxi omaduste kokkuvõttesse ja pakendi infolehele vaktsiini ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The vaccine must not be used in people who have problems with their immune system, either because they have a disease such as leukaemia, lymphoma, acquired immune deficiency syndrome (AIDS), or because they are taking medicines that affect the immune system.
Estonian: Vaktsiini ei tohi kasutada ka patsientidel, kellel on immuunsüsteemi probleeme kas haiguse tõttu, näiteks leukeemia, lümfoomi või omandatud immuunpuudulikkuse sündroomi (AIDS) tõttu, või immuunsüsteemi mõjutava ravimi tõttu.
English: The effect was seen both in patients aged between 50 and 59 years and in those aged 60 years and older.
Estonian: Sama toime oli nii 50-59aastastel kui ka vähemalt 60-aastastel patsientidel.
English: In studies, the most common side effects with Zostavax are reactions at the site of the injection (redness, pain, swelling, itching, warmth and bruising), headache and pain in the arm or leg.
Estonian: Uuringutes olid Zostavaxi kõige sagedamad kõrvalnähud süstekoha reaktsioonid (punetus, valu, turse, sügelus, soojatunne ja verevalum), peavalu ning käe- või jalavalu.
English: The CHMP decided that Zostavax's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zostavaxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: For more information about treatment with Zostavax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zostavaxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The main study of Zostavax compared the vaccine with placebo (a dummy) vaccine in around 39,000 patients aged between 59 and 99 years.
Estonian: Zostavaxi põhiuuringus võrreldi vaktsiini platseeboga (näiv ravim) ligikaudu 39 000 patsiendil vanuses 59-99 aastat.
English: Other information about Zostavax
Estonian: Muu teave Zostavaxi kohta
English: Why has Zostavax been approved?
Estonian: Miks Zostavax heaks kiideti?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zostavax.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas vaktsiini ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas vaktsiini kasutada.
English: The risk of developing shingles increases with age and seems to be linked to a decline in immunity (protection) against varicella-zoster virus.
Estonian: Vöötohatise tekke risk suureneb vanusega ja näib olevat seotud tuulerõugeviiruse vastase immuunsuse vähenemisega.
English: What is the risk associated with Zostavax?
Estonian: Mis riskid Zostavaxiga kaasnevad?
English: Fewer people developed shingles after vaccination with Zostavax than placebo: 315 of the 19,254 patients who received Zostavax had shingles during the study, compared with 642 of the 19,247 who received placebo.
Estonian: Zostavaxiga vaktsineeritutel tekkis vöötohatis väiksemal arvul inimestel kui platseebosüsti saanutel: vöötohatis tekkis uuringu ajal 315 patsiendil 19 254st, kes olid saanud Zostavaxi, ja 642 patsiendil 19 247st, kes olid saanud platseebot.
English: The rash takes usually several weeks to clear, and may be followed by severe long-lasting pain (post-herpetic neuralgia) in the area where the rash was.
Estonian: Lööve püsib tavaliselt mitu nädalat ning pärast seda võib tekkida lööbe kohal tugev pikaajaline valu (herpesejärgne neuralgia).
English: The additional two studies showed that patients vaccinated with Zostavax had blood levels of antibodies against varicella-zoster virus that were about two to three times higher four weeks after vaccination.
Estonian: Mõlemas lisauuringus selgus, et Zostavaxiga vaktsineeritud patsientide vere tuulerõugeviiruse vastaste antikehade sisaldus oli neli nädalat hiljem ligikaudu 2-3 korda suurem.
English: Zostavax must not be used in people who are hypersensitive (allergic) to any of the components of the vaccine, or to any substances found at trace (very low) levels in the vaccine such as neomycin (an antibiotic).
Estonian: Zostavaxi ei tohi kasutada patsientidel, kes on ülitundlikud (allergilised) vaktsiini mis tahes koostisaine suhtes või vaktsiinis väga väikeses kontsentratsioonis sisalduvate ainete (näiteks antibiootikumi neomütsiini) suhtes.
English: Herpes zoster, or shingles, is a disease caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox.
Estonian: Herpes zoster ehk vöötohatis on haigus, mida põhjustab tuulerõugeviirus - sama viirus, mis põhjustab tuulerõugeid.
English: Zostavax was also more effective than placebo in preventing post-herpetic neuralgia: 27 of the Zostavax patients had post-herpetic neuralgia, compared with 80 in the placebo group.
Estonian: Zostavax oli platseebost efektiivsem ka herpesejärgse neuralgia ennetamisel: herpesejärgne neuralgia esines 27 Zostavaxi patsiendil ja 80 platseeborühma patsiendil.
English: This is a summary of the European public assessment report (EPAR) for Zostavax.
Estonian: Käesolev dokument on vaktsiini Zostavax Euroopa avaliku hindamisaruande kokkuvõte.
English: Zostavax is used to vaccinate people aged 50 years or older, to prevent herpes zoster (also known as zoster or shingles) and the long-lasting nerve pain that may follow the disease (post-herpetic neuralgia).
Estonian: Zostavaxi kasutatakse vähemalt 50-aastaste inimeste vaktsineerimiseks, et ennetada vöötohatist (herpes zoster) ning sellele järgneda võivat pikaaegset närvivalu (herpesejärgset neuralgiat).
English: Zostavax is given as a single dose injected under the skin or into the muscle, preferably around the shoulder.
Estonian: Zostavaxi manustatakse ühe annusena süstituna naha alla või lihasesse, eelkõige õlalihasesse.
English: Sometimes, after many years, and for reasons which are not fully understood, the virus becomes active again, and the patient develops shingles, a painful,
Estonian: Mõnikord aktiveerub see viirus seni veel mitte täiesti teada olevatel põhjustel aastaid hiljem uuesti ning patsiendil tekib tavaliselt ühes kehapiirkonnas vöötohatis, mis on valulik ja villiline lööve.
English: Zostavax is a vaccine that was shown to ‘boost' this immunity, protecting against shingles and the pain associated with it.
Estonian: Zostavax on vaktsiin, mis tõestatult süvendab konkreetselt sellist immuunsust, mis kaitseb vöötohatise ning sellega kaasneva valu vastu.
English: The main measure of effectiveness was based on the number of people who developed shingles and post-herpetic pain.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis vöötohatis ja herpesejärgne neuralgia.
English: For the full list of all side effects reported with Zostavax, see the package leaflet.
Estonian: Zostavaxi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The active substance is the attenuated (weakened) varicella-zoster virus.
Estonian: Vaktsiini toimeaine on nõrgestatud tuulerõugeviirus.
English: Two further studies looked at Zostavax in over 1,000 patients aged 50 years or older, of whom 389 were between 50 and 59 years of age.
Estonian: Kahes täiendavas uuringus vaadeldi Zostavaxi kasutamist enam kui 1000-l vähemalt 50-aastasel patsiendil, kellest 389 olid 50-59-aastased Uuringutes vaadeldi vaktsiini suutlikkust stimuleerida veres tuulerõugeviiruse vastaseid antikehi neli nädalat pärast süstimist.
English: What is Zostavax used for?
Estonian: Milleks Zostavaxi kasutatakse?
English: Zostavax is a vaccine that is available as a powder and solvent to be made up into a solution for injection.
Estonian: Zostavax on vaktsiin, mida turustatakse süstelahuse pulbri ja lahustina.
English: What benefit has Zostavax shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zostavaxi kasulikkus?
English: The vaccine can only be obtained with a prescription.
Estonian: Zostavax on retseptivaktsiin.
English: How does Zostavax work?
Estonian: Kuidas Zostavax toimib?
English: How is Zostavax used?
Estonian: Kuidas Zostavaxi kasutatakse?
English: Zostavax shingles (herpes zoster) vaccine (live)
Estonian: Zostavax vöötohatise elusvaktsiin
English: Shingles develops in people who have had chickenpox earlier in life, generally as a child. After chickenpox, the varicella-zoster virus stays in the body, in the nervous system, in a ‘dormant' (inactive) state.
Estonian: Vöötohatis tekib inimestel, kellel on varem elus olnud tuulerõuged - tavaliselt lapsena.
English: What is Zinnat?
Estonian: Mis on Zinnat?
English: The European Commission issued a decision on 23 August 2012.
Estonian: Euroopa Komisjon tegi otsuse 23. augustil 2012.
English: Zinnat is marketed in all EU Member States, as well as Iceland.
Estonian: Zinnatit turustatakse kõikides ELi liikmesriikides ja Islandil.
English: Why was Zinnat reviewed?
Estonian: Miks Zinnati taotlus uuesti läbi vaadati?
English: It is also available under other trade names: Cefuroxima Allen, Cefuroxima Solasma, Elobact, Nivador, Oraxim, Selan, Zinadol, Zipos, Zoref.
Estonian: Ravimit turustatakse ka teiste kaubanduslike nimetuste all: Cefuroxima Allen, Cefuroxima Solasma, Elobact, Nivador, Oraxim, Selan, Zinadol, Zipos, Zoref.
English: Zinnat should be used twice a day at different doses depending on the condition it is used to treat.
Estonian: Zinnatit tuleb kasutada kaks korda ööpäevas erinevas annuses, sõltuvalt ravi vajavast haigusest.
English: On 24 May 2012, the European Medicines Agency completed a review of Zinnat.
Estonian: 24. mail 2012 lõpetas Euroopa Ravimiamet Zinnati läbivaatamise.
English: The CHMP also harmonised other sections of the SmPC including sections 4.3 (contra-indications) and 4.4 (special warnings and precautions for use).
Estonian: Inimravimite komitee ühtlustas ka teised ravimi omaduste kokkuvõtte lõigud, sh lõigud 4.3 (Vastunäidustused) ja 4.4 (Erihoiatused ja ettevaatusabinõud kasutamisel).
English: Having harmonised the indications, the CHMP also harmonised the recommendations on the use of Zinnat in adults and children and in patients with reduced kidney and liver function.
Estonian: Pärast näidustuste ühtlustamist ühtlustas inimravimite komitee ka Zinnati kasutamissoovitused täiskasvanutel ja lastel ning halvenenud neeru- ja maksatalitlusega patsientidel.
English: Questions and answers on Zinnat and associated names (cefuroxime axetil, 125, 250 and 500 mg tablets and 125, 250 and 500 mg granules for oral suspension) EMA/CHMP/339191/2012
Estonian: Teave Zinnati ja sarnaste nimetuste kohta (tsefuroksiimaksetiil, 125, 250 ja 500 mg tabletid ning 125, 250 ja 500 mg suukaudse suspensiooni graanulid) EMA/CHMP/339191/2012
English: The CHMP concluded that Zinnat should be used in adults and children from three months of age for the following conditions:
Estonian: Inimravimite komitee otsustas, et Zinnatit tuleb kasutada täiskasvanutel ja lastel alates 3. elukuust järgmiste seisundite raviks: